Literature DB >> 1855072

ENSG 1-randomised study of high-dose melphalan in neuroblastoma.

C R Pinkerton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1855072

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  5 in total

1.  High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors.

Authors:  Antonio Pérez-Martínez; Victor Quintero; Marta González Vicent; Julián Sevilla; Miguel Angel Díaz; Luis Madero
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 2.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 3.  High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.

Authors:  Bilgehan Yalçin; Leontien C M Kremer; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2015-10-05

4.  Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment.

Authors:  R Luksch; M Podda; L Gandola; D Polastri; L Piva; R Castellani; P Collini; M Massimino; G Cefalo; M Terenziani; A Ferrari; M Casanova; F Spreafico; C Meazza; F Bozzi; A Marchianò; F Ravagnani; F Fossati-Bellani
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

5.  The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis.

Authors:  D Frappaz; D Perol; J Michon; C Berger; C Coze; J L Bernard; J M Zucker; T Philip
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.